Real world data back Sanofi’s Toujeo for type I diabetes
Sanofi has unveiled real-world data from the UK showing the efficacy of its long-acting basal insulin analogue Toujeo in treating patients with type I diabetes.
The data, presented for the first time at ENDO 2018, the Endocrine Society’s 100th Annual Meeting & Expo, in Chicago, showed that the drug is linked with statistically significant improvements in HbA1c in patients with the condition, with a mean difference of from baseline to month six of –4.4 mmol/mol.
The study also showed no change in the number of patients reporting either diabetic ketoacidosis (DKA) or severe hypoglycaemia after starting treatment with Toujeo (Gla-300).
Read more: http://www.pharmatimes.com/news/real_world_data_back_sanofis_toujeo_for_type_i_diabetes_1228401
The data, presented for the first time at ENDO 2018, the Endocrine Society’s 100th Annual Meeting & Expo, in Chicago, showed that the drug is linked with statistically significant improvements in HbA1c in patients with the condition, with a mean difference of from baseline to month six of –4.4 mmol/mol.
The study also showed no change in the number of patients reporting either diabetic ketoacidosis (DKA) or severe hypoglycaemia after starting treatment with Toujeo (Gla-300).
Read more: http://www.pharmatimes.com/news/real_world_data_back_sanofis_toujeo_for_type_i_diabetes_1228401
